Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2
Authors:
- Jasper Fuk-Woo ChanJCJasper Fuk-Woo Chan
Open Access
- 29 August 2022
- journal article
- research article
- Published by Elsevier in Cell Reports Medicine
- Vol. 3 (9) , 100743
Abstract
No abstract availableKeywords
Funding Information
- General Research Fund of Shanghai Normal University (17118621, 17123920, C7060-21G, T11-709/21-N)
- Li Ka Shing Faculty of Medicine, University of Hong Kong
- Health and Medical Research Fund (20190652, CID-HKU1-5, COVID1903010-Projects 7)
- Sanming Project of Medicine in Shenzen Municipality (SZSM201911014)
- National Key Research and Development Program of China
- University of Hong Kong
- Food and Health Bureau
- Science and Technology Program of Hunan Province (YSPTZX202004, ZDKJ202003)
- Research Grants Council, University Grants Committee
- Innovation and Technology Commission
This publication has 26 references indexed in Scilit:
- Activity of convalescent and vaccine serum against SARS-CoV-2 OmicronNature, 2021
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodiesNature, 2021
- Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralizationNature, 2021
- Emerging SARS-CoV-2 variants expand species tropism to murinesEBioMedicine, 2021
- TMPRSS2 expression dictates the entry route used by SARS‐CoV‐2 to infect host cellsThe EMBO Journal, 2021
- Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severityScience Advances, 2021
- Host and viral determinants for efficient SARS-CoV-2 infection of the human lungNature Communications, 2021
- A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung CellsMolecular Cell, 2020
- Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational studyThe Lancet Microbe, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020